Recent advances in neutralizing the IL-6 pathway in arthritis

References

• MalemudCJPearlmanETargeting JAK/STAT signaling pathway in inflammatory diseasesCurr Signal Transduct Ther20094201221
   Web of Science ®Google Scholar
• ChristodoulouCChoyEHJoint inflammation and cytokine inhibition in rheumatoid arthritisClin Exp Med200661131916550339
   PubMed Web of Science ®Google Scholar
• Rose-JohnSSchellerJElsonGJonesSAInterleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancerJ Leukoc Biol200680222723616707558
   PubMed Web of Science ®Google Scholar
• KishimotoTInterleukin-6: discovery of a pleiotropic cytokineArthritis Res Ther20068Suppl 2S2
   PubMed Web of Science ®Google Scholar
• NishimotoNKishimotoTInterleukin-6: from bench to bedsideNat Clin Pract Rheumatol200621161962617075601
   PubMedGoogle Scholar
• SmolenJSMainiRNInterleukin-6: a new therapeutic targetArthritis Res Ther20068Suppl 2S516899109
   PubMed Web of Science ®Google Scholar
• GabayCInterleukin-6 and chronic inflammationArthritis Res Ther20068Suppl 2S3
   PubMed Web of Science ®Google Scholar
• LipskyPEInterleukin-6 and rheumatic diseasesArthritis Res Ther20068Suppl 2S4
   PubMed Web of Science ®Google Scholar
• Paul-PletzerKTocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disordersDrugs Today (Barc)200642955957617028666
   PubMed Web of Science ®Google Scholar
• CrawfordMMorelandLInterleukin-6 receptor antagonist as therapy for rheumatoid arthritisCurr Rheumatol Rep20079539339417969944
   PubMedGoogle Scholar
• NishimotoNKishimotoKHumanized antihuman IL-6 antibody, tocilizumabHandb Exp Pharmacol200818115116018071945
   PubMedGoogle Scholar
• SebbaATocilizumab: the first interleukin-6 receptor inhibitorAm J Health Syst Pharm200865151413141818653811
   PubMed Web of Science ®Google Scholar
• OldfieldVDhillonSPloskerGLTocilizumab: a review of its use in the management of rheumatoid arthritisDrugs200969560963219368420
   PubMed Web of Science ®Google Scholar
• KinjyoIOhishiMShoudaTKobayashiTYoshimuraAPositive and negative roles of IL-6, STAT3, and SOCS3 in inflammatory arthritisAdv Exp Med Biol200760211312417966396
   PubMed Web of Science ®Google Scholar
• NauglerWEKarinMThe wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends Mol Med200814310911918261959
   PubMed Web of Science ®Google Scholar
• FonsecaJESantosMJCanhãoHChoyEInterleukin-6 as a key player in systemic inflammation and joint destructionAutoimmun Rev20098753854219189867
   PubMed Web of Science ®Google Scholar
• Rose-JohnSWaetzigGHSchellerJGrötzingerJSeegertDThe IL-6/sIL-6R complex as a novel target for therapeutic approachesExpert Opin Ther Targets200711561362417465721
   PubMed Web of Science ®Google Scholar
• FinckhAGabayCAt the horizon of innovative therapy in rheumatology: new biologic agentsCurr Opin Rheumatol200820326927518388517
   PubMed Web of Science ®Google Scholar
• SchettGReview: immune cells and mediators in inflammatory arthritisAutoimmunity200841322422918365836
   PubMed Web of Science ®Google Scholar
• BrennanFMMcInnesIBEvidence that cytokines play a role in rheumatoid arthritisJ Clin Invest2008118113537354518982160
   PubMed Web of Science ®Google Scholar
• ChoyEInhibiting interleukin-6 in rheumatoid arthritisCurr Rheumatol Rep200810541341718817647
   PubMedGoogle Scholar
• RajDSRole of interleukin-6 in the anemia of chronic diseaseSemin Arthritis Rheum200938538238818336871
   PubMed Web of Science ®Google Scholar
• MimaTNishimotoNClinical value of blocking IL-6 receptorCurr Opin Rheumatol200921322423019365268
   PubMed Web of Science ®Google Scholar
• De BenedettiFTargeting interleukin-6 in pediatric rheumatic diseasesCurr Opin Rheumatol200921553353719593141
   PubMed Web of Science ®Google Scholar
• YouinouPJaminCThe weight of interleukin-6 in B cell-related autoimmune disordersAutoimmun2009323–4206210
   Web of Science ®Google Scholar
• de PabloPChappleILBuckleyCDDietrichTPeriodontitis in systemic rheumatic diseasesNat Rev Rheumatol20095421822419337286
   PubMed Web of Science ®Google Scholar
• TakatoriHKannoYChenZO’SheaJJNew complexities in helper T cell fate determination and the implications for autoimmune diseasesMod Rheumatol200818653354118679768
   PubMed Web of Science ®Google Scholar
• MalemudCJReddySKTargeting cytokines, chemokines and adhesion molecules in rheumatoid arthritisCurr Rheum Rev20084219234
   Google Scholar
• BettelliEKornTKuchrooVKTh17; the third member of the effector T cell trilogyCurr Opin Immunol200719665265717766098
   PubMed Web of Science ®Google Scholar
• Layh-SchmittGColbertRAThe interleukin-23/interleukin-17 axis in spondyloarthritisCurr Opin Rheumatol200820439239718525350
   PubMed Web of Science ®Google Scholar
• ChenZO’SheaJJTh17 cells: a new fate for differentiating helper T cellsImmunol Res20084128710218172584
   PubMed Web of Science ®Google Scholar
• KornTBettelliEOukkaMKuchrooVKIL-17 and Th17 cellsAnnu Rev Immunol20092748551719132915
   PubMed Web of Science ®Google Scholar
• MiharaMOhsugiYKishimotoTEvidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interleukin-6 receptor antibodyBiofactors2009351475119319845
   PubMed Web of Science ®Google Scholar
• OguraHMurakamiMOkuyamaYInterleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 productionImmunity200829462863618848474
   PubMed Web of Science ®Google Scholar
• NishiharaMOguraHUedaNIL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady stateInt Immunol200719669570217493959
   PubMed Web of Science ®Google Scholar
• MaitraUDavisSReillyCMLiLDifferential regulation of FoxP3 and IL-17 expression in CD4 T helper cells by IRAK-1J Immunol200918295763576919380824
   PubMed Web of Science ®Google Scholar
• FujimotoMSeradaSMiharaMInterleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responsesArthritis Rheum200858123710371919035481
   PubMed Web of Science ®Google Scholar
• LeeJHChoMLKimJIInterleukin-17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1β and IL-6 production in autoimmune miceJ Rheumatol200936468469219228664
   PubMed Web of Science ®Google Scholar
• OspeltCBrentanoFRengelYOverexpression of toll-like receptor 3 and 4 in synovial tissue from patients with early rheumatoid arthritis. Toll-like receptor expression in early and longstanding arthritisArthritis Rheum200858123684369219035519
   PubMed Web of Science ®Google Scholar
• PalmerCDMutchBEWorkmanSMcDaidJPHorwoodNJFoxwellBMBmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NF-κB activityBlood200811141781178818025155
   PubMed Web of Science ®Google Scholar
• MalemudCJRole of non-receptor tyrosine and threonine kinase inhibitorsGarcía-FoncillasJMolecular Biology of Cancer: Toward New TherapiesBarcelonaProus Science SA2009537555
   Google Scholar
• PalmerCDMutchBEPageTHHorwoodNJFoxwellBMBmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblastsBiochem Biophys Res Commun2008370459960218402776
   PubMed Web of Science ®Google Scholar
• HashizumeMHayakawaNMiharaMIL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17Rheumatology (Oxford)200847111635164018786965
   PubMed Web of Science ®Google Scholar
• InoueTHammakerDBoyleDLFiresteinGSRegulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytesJ Immunol200517474301430615778394
   PubMed Web of Science ®Google Scholar
• MalemudCJInhibitors of stress-activated/mitogen-activated protein kinase pathwaysCurr Opin Pharmacol20077333934317398158
   PubMed Web of Science ®Google Scholar
• MalemudCJMAP kinasesBuckwalterJLotzMStoltzJFOsteoarthritis, Inflammation and Degradation: A ContinuumAmsterdamIOS Press200799117
   Google Scholar
• InoueTBoyleDLCorrMMitogen-activated protein kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritisProc Natl Acad Sci U S A2006103145484548916567640
   PubMed Web of Science ®Google Scholar
• YoshikawaTHammakerDBoyleDLRole of MAPK kinase 6 in arthritis; distinct mechanism of action in inflammation and cytokine expressionJ Immunol200918321360136719561096
   PubMed Web of Science ®Google Scholar
• SinghRAhmedSMalemudCJGoldbergVMHaqqiTMEpigallocatechin-3-gallate selectively inhibits interleukin-1β-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytesJ Orthop Res200321110210912507586
   PubMed Web of Science ®Google Scholar
• SinghRAhmedSIslamNGoldbergVMHaqqiTMEpigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes. Suppression of nuclear factor κB activation by degradation of the inhibitor of nuclear factor κBArthritis Rheum20024682079208612209512
   PubMed Web of Science ®Google Scholar
• AhmedSMarotteHKwanKEpigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 productionProc Natl Acad Sci U S A200810538146921469718796608
   PubMed Web of Science ®Google Scholar
• LeeCHShiehDCTzengCYBradykinin-induced IL-6 expression through bradykinin B2 receptor, phospholipase C, protein kinase Cδ and NF-κB pathway in human synovial fibroblastsMol Immunol200845143693370218621420
   PubMed Web of Science ®Google Scholar
• AndersonKCProteasome inhibitors in multiple myelomaSemin Oncol2009362 SupplS20S2619393832
   PubMed Web of Science ®Google Scholar
• LeeSWKimJHParkYBLeeSKBortezomib attenuates murine collagen-induced arthritisAnn Rheum Dis2008 Epub ahead of print19054826
   PubMed Web of Science ®Google Scholar
• MalemudCJGillespieHJThe role of apoptosis in arthritisCurr Rheum Rev20051131142
   Google Scholar
• MalemudCJGrowth hormone, VEGF and FGF; Involvement in rheumatoid arthritisClin Chim Acta20073751–2101916893535
   PubMed Web of Science ®Google Scholar
• RochasCHillionSYouinouPJaminCDevauchelle-PensecVRAG-mediated secondary rearrangements of B-cell antigen receptors in rheumatoid synovial tissueAutoimmun Rev20077215515918035327
   PubMed Web of Science ®Google Scholar
• RochasCHillionSSarauxATransmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytesArthritis Rheum20096051261127119404965
   PubMed Web of Science ®Google Scholar
• MackayFSierroFGreySTGordonTPThe BAFF/APRIL system; an important player in systemic rheumatic diseasesCurr Dir Autoimmun2005824326515564724
   PubMedGoogle Scholar
• NgLGMackayCRMackayFThe BAFF/APRIL system: life beyond B lymphocytesMol Immunol200542776377215829264
   PubMed Web of Science ®Google Scholar
• NgLGNgCHWoehlBBAFF costimulation of Toll-like receptor-activated B-1 cellsEur J Immunol20063671837184616791880
   PubMed Web of Science ®Google Scholar
• VugmeysterYSeshasayeeDChangWA soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeysAm J Pathol2006168247648916436662
   PubMed Web of Science ®Google Scholar
• Lai Kwan LamQKing Hung KoOZhengBJLuLLocal BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritisProc Natl Acad Sci U S A2009105391499314998
   Web of Science ®Google Scholar
• DaridonCBurmesterGRDörnerTAnticytokine therapy impacting on B cells in autoimmune diseasesCurr Opin Rheumatol200921320521019346949
   PubMed Web of Science ®Google Scholar
• EhlingASchäfflerAHerfarthHThe potential of adiponectin in driving arthritisJ Immunol200617674468447816547285
   PubMed Web of Science ®Google Scholar
• HaugenFDrevonCAActivation of nuclear factor-κB by high molecular weight and globular adiponectinEndocrinology2007148115478548617702846
   PubMed Web of Science ®Google Scholar
• TangCHChiuYCTanTWYangRSFuWMAdiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38 and NF-κB pathwayJ Immunol200717985483549217911635
   PubMed Web of Science ®Google Scholar
• LeeSWKimJHParkMCParkYBLeeSKAdiponectin mitigates the severity of arthritis in mice with collagen-induced arthritisScand J Rheumatol200837426026818612926
   PubMed Web of Science ®Google Scholar
• MalemudCJAnticytokine therapy for osteoarthritis; Evidence to dateDrugs Aging2009
   Web of Science ®Google Scholar
• HamsEColmontCSDioszeghyVOncostatin M receptor-β signaling limits monocyte cell recruitment in acute inflammationJ Immunol200818132174218018641356
   PubMed Web of Science ®Google Scholar
• LukTMalamZMarshallJCPre-B cell colony-enhancing factor (PBEF)/visfatin; a novel mediator of innate immunityJ Leukoc Biol2008844804816
   Web of Science ®Google Scholar
• NowellMARichardsPJFieldingCARegulation of pre-B cell colony enhancing factor by STAT-3-dependent interleukin-6 trans-signaling. Implications in the pathogenesis of rheumatoid arthritisArthritis Rheum20065472084209516802343
   PubMed Web of Science ®Google Scholar
• BrantanoFSchorrOOspeltCPre-B cell colony enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with pro-inflammatory and matrix-degrading activitiesArthritis Rheum20075692829283917763446
   PubMed Web of Science ®Google Scholar
• NakamuraTClinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritisMod Rheumatol200818210911818369528
   PubMed Web of Science ®Google Scholar
• KogaTTorigoshiTMotokawaSSerum amyloid A-induced IL-6 production by rheumatoid synoviocytesFEBS Lett2008582557958518243142
   PubMed Web of Science ®Google Scholar
• UchiyamaYYorozuKHashizumeMMoriyaYMiharaMTocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritisBiol Pharm Bull20083161159116318520048
   PubMed Web of Science ®Google Scholar
• KatoAMatsuoSTakaiHUchiyamaYMiharaMSuzukiMEarly effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey modelExp Mol Pathol200884326227018511040
   PubMed Web of Science ®Google Scholar
• BockermannRSchubertDKamradtTHolmdahlRInduction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomeraseArthritis Res Ther200576R1316R132416277685
   PubMed Web of Science ®Google Scholar
• MatsumotoIZhangHYasukochiTTherapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritisArthritis Res Ther2008103R6618534002
   PubMed Web of Science ®Google Scholar
• IwanamiKMatsumotoTTanaka-WatanabeYCrucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomeraseArthritis Rheum200858375476318311788
   PubMed Web of Science ®Google Scholar
• WangJXTangWZhouRThe new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responsesBr J Pharmacol200815361303131018264129
   PubMed Web of Science ®Google Scholar
• SuzukiMHashizumeMYoshidaHMiharaMAnti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody; effect on the expression of chemokine and adhesion moleculesRheumatol Int2009 Epub ahead of print19466425
   PubMed Web of Science ®Google Scholar
• WongPKKQuinnJMSimsNAvan NieuwenhuijzeACampbellIKWicksJPInterleukin-6 modulates production of T-lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesisArthritis Rheum200654115816816385511
   PubMed Web of Science ®Google Scholar
• LotzeMTTraceyKJHigh-mobility group box 1 protein (HMGB1); nuclear weapon in the immune arsenalNat Rev Immunol20055433134215803152
   PubMed Web of Science ®Google Scholar
• ParkJSGamboni-RobertsonFHeQHigh mobility group box 1 protein interacts with multiple Toll-like receptorsAm J Physiol Cell Physiol20062903C917C92416267105
   PubMed Web of Science ®Google Scholar
• OrlovaVVChoiEYXieCA novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1 integrinEMBO J20072641129113917268551
   PubMed Web of Science ®Google Scholar
• PulleritsRJonssonIMKolliasGTarkowskiAInduction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signallingArthritis Res Ther2008103R7218582368
   PubMed Web of Science ®Google Scholar
• MiliciAJKudlaczEMAudolyLZwillichSChangelianPCartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritisArthritis Res Ther2008191R14
   Web of Science ®Google Scholar
• TsujiFYoshimiMKatsutaOTakaiMIshiharaKAonoHPoint mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J miceBMC Musculoskelet Disord2009102319228423
   PubMed Web of Science ®Google Scholar
• SawaSKamimuraDJinGHAutoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7 dependent homeostatic proliferation of CD4+ cellsJ Exp Med200620361459147016717113
   PubMed Web of Science ®Google Scholar
• GallePJensenLAnderssonCVaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally-induced inflammationInt Immunopharmacol20077131704171317996680
   PubMed Web of Science ®Google Scholar
• PerryMGRichardsLHarbuzMSJessopDSKirwanJRSequential synovial fluid sampling suggests plasma and synovial fluid IL-6 vary independently in rheumatoid arthritisRheumatology (Oxford)200645222923016352642
   PubMed Web of Science ®Google Scholar
• PerryMGKirwanJRJessopDSHuntLPOvernight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritisAnn Rheum Dis2009681636818375536
   PubMed Web of Science ®Google Scholar
• MatsumotoTTsurumotoTShindoHInterleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membraneRheumatol Int200626121096110016738904
   PubMed Web of Science ®Google Scholar
• KarlsonEWChibnikLBTworogerSSBiomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studiesArthritis Rheum200960364165219248103
   PubMed Web of Science ®Google Scholar
• de JagerWHoppenreijsEPWulffraatNMWedderburnLRKuisWPrakkenBJBlood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; a cross-sectional studyAnn Rheum Dis200766558959817170049
   PubMed Web of Science ®Google Scholar
• AleniusGMErikssonCRantapää DahlqvistSInterleukin-6 and soluble interleukin-2-receptor α-markers of inflammation in patients with psoriatic arthritis?Clin Exp Rheumatol200927112012319327240
   PubMed Web of Science ®Google Scholar
• SørensenLKHavemose-PoulsenABendtzenKHolmstrupPAggressive periodontitis and chronic arthritis; blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitorsJ Periodontol200980228228919186969
   PubMed Web of Science ®Google Scholar
• AmitalHBarakVWinklerRERubinowAImpact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritisAnn N Y Acad Sci2007111064966017911480
   PubMed Web of Science ®Google Scholar
• BuchMHReeceRJQuinnMAThe value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)Rheumatology (Oxford)200847101469147518660510
   PubMed Web of Science ®Google Scholar
• SundbergEGrundtmanCAf KlintESystemic TNF blockade does not modulate synovial expression of pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical studyArthritis Res Ther2008102R3318346273
   PubMed Web of Science ®Google Scholar
• HarrisHERaucciAAlarmin(g) news about danger; workshop on innate danger signals and HMGB1EMBO Rep20067877477816858429
   PubMed Web of Science ®Google Scholar
• KnudsenLSOstergaardMBaslundBPlasma IL-6, plasma VEGF and serum YKL-40; relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexateScand J Rheumatol200635648949117343261
   PubMed Web of Science ®Google Scholar
• KnudsenLSKlarlundMSkjødtHBiomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcomeJ Rheumatol20083571277128718597410
   PubMed Web of Science ®Google Scholar
• Cordiali-FeiPArdigòMMastroianniASerum cytokine and bioumoral immunological characterization of psoriatic patients in long term etanercept treatmentInt J Immunopathol Pharmacol200821364364918831932
   PubMed Web of Science ®Google Scholar
• KamijoSNakajimaAKamataKKurosawaHYagitaHOkumuraKInvolvement of TWEAK/Fn14 interaction in the synovial inflammation of RARheumatology (Oxford)200847444245018310134
   PubMed Web of Science ®Google Scholar
• ParkMCChungSJParkYBLeeSKRelationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritisScand J Rheumatol200837317317818465450
   PubMed Web of Science ®Google Scholar
• BadotVGalantCNzeusseu ToukapAGene expression profiling in the synovium identifies predictive signature of absence of response to adalimumab therapy in rheumatoid arthritisArthritis Res Ther2009112R5719389237
   PubMed Web of Science ®Google Scholar
• BongartzTTocilizumab for rheumatoid and juvenile idiopathic arthritisLancet2008371961796196318358909
   PubMed Web of Science ®Google Scholar
• YokotaSImagawaTMoriMEfficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trialLancet20083719617998100618358927
   PubMed Web of Science ®Google Scholar
• PeakeNJKhawajaKMyersAInterleukin-6-signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptorRheumatology (Oxford)200645121485148916690760
   PubMed Web of Science ®Google Scholar
• NakajimaSNarutoTMiyamaeTImprovement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6-receptor monoclonal antibody tocilizumabMod Rheumatol2009191424618726067
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI); evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study); a double-blind, placebo-controlled, randomised trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour factor biologicals; results from a 24-week multicentre randomised placebo-controlled trialAnn Rheum Dis200867111516152318625622
   PubMed Web of Science ®Google Scholar
• FunahashiKKoyanoSMiuraTHagiwaraFOkudaKMatsubaraTEfficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 levelsMod Rheumatol2009 Epub ahead of print19609487
   PubMed Web of Science ®Google Scholar
• StraubRHHärlePYamanaSAnti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trialArthritis Rheum20065461778178516729287
   PubMed Web of Science ®Google Scholar
• RhoYHSolusJSokkaTAdipocytokines are associated with radiographic joint damage in rheumatoid arthritisArthritis Rheum20096071906191419565493
   PubMed Web of Science ®Google Scholar
• BarnesTCMootsRJTargeting oncostatin M in the treatment of rheumatoid arthritisTakPPProgress in Inflammation Research New Therapeutic Targets in Rheumatoid ArthritisBaselBirkhäuser2009181191
   Google Scholar
• EnomotoHSaitoSYabeHToyamaYTomatuTThe levels of leukemia inhibitory factor in synovial tissue of patients with rheumatoid arthritis; inflammation and other proinflammatory cytokinesMod Rheumatol200313212112824387170
   PubMedGoogle Scholar
• JazayeriJADe WeerdNRayeWKivivuoriSZabihiECarrollGJIn vitro evaluation of leukemia inhibitory factor receptor antagonists as candidate therapeutics for inflammatory arthritisJ Interferon Cytokine Res200727428128917477816
   PubMed Web of Science ®Google Scholar
• UpadhyayASharmaGKivivuoriSRole of LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytesCytokine200946333233819342253
   PubMed Web of Science ®Google Scholar
• MetzSNaethGHeinrichPCMϋller-NewenGNovel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptorsJ Biol Chem2008283105985599518174171
   PubMed Web of Science ®Google Scholar
• LevesqueMCClairEWStB-cell-directed therapies for autoimmune diseases and correlates of disease response and relapseJ Allergy Clin Immunol20081211132118206502
   PubMed Web of Science ®Google Scholar
• DörnerTRadbruchABurmesterGRB-cell-directed therapies for autoimmune diseasesNat Rev Rheumatol20095843344119581902
   PubMed Web of Science ®Google Scholar
• FabreSGuissetCTatemLProtein biochip array technology to monitor rituximab in rheumatoid arthritisClin Exp Immunol2009155339540219220830
   PubMed Web of Science ®Google Scholar
• MalemudCJSchulteMEIs there a final common pathway for arthritis?Fut Rheumatol20083253268
   Google Scholar
• AndreasKL bkeCHäuplTKey regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro studyArthritis Res Ther2008101R918205922
   PubMed Web of Science ®Google Scholar
• AndreasKHäuplTL bkeCAntirheumatic drug response signatures in human chondrocytes; potential molecular targets to stimulate cartilage regenerationArthritis Res Ther2009111R1519192274
   PubMed Web of Science ®Google Scholar
• HuebnerJLKrausVBAssessment of the utility of biomarkers of osteoarthritis in the guinea pigOsteoarthritis Cartilage200614992393016679035
   PubMed Web of Science ®Google Scholar
• LeyCEkmanSRonéusBElorantaMLInterleukin-6 and high mobility group box protein-1 in synovial membranes and osteochondral fragments in equine osteoarthritisRes Vet Sci200986349049719041991
   PubMed Web of Science ®Google Scholar
• ChaeHJHaKCLeeGYInterleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblastsImmunopharmacol Immunotoxicol200729215517217849265
   PubMed Web of Science ®Google Scholar
• BurragePSMixKSBrinckerhoffCEMatrix metalloproteinases; role in arthritisFront Biosci20061152954316146751
   PubMed Web of Science ®Google Scholar
• StraubRHWolffCFassoidAAntiinflammatory role of endomorphins in osteoarthritis, rheumatoid arthritis, and adjuvant-induced polyarthritisArthritis Rheum200858245646618240240
   PubMed Web of Science ®Google Scholar
• NakajimaSNarutoTMiyamaeTInterleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cellsCytokine2009472919719535264
   PubMed Web of Science ®Google Scholar
• TobinAMKirbyBTNF α inhibitors in the treatment of psoriasis and psoriatic arthritisBiodrugs2005191475715691217
   PubMed Web of Science ®Google Scholar
• StroberBTellerCYamauchiPEffects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritisBr J Dermatol2008159232233018503600
   PubMed Web of Science ®Google Scholar
• Villa-ForteAAnticytokine therapy in non-rheumatoid arthritis indications in 2009Curr Opin Rheumatol200921325125519342955
   PubMed Web of Science ®Google Scholar
• MastroianniAMinutilliEMussiACytokine profiles during infliximab monotherapy in psoriatic arthritisBr J Dermatol2005153353153616120138
   PubMed Web of Science ®Google Scholar
• Cordiali-FeiPTrentoED’AgostoGEffective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesionsAnn NY Acad Sci2007111057858917911474
   PubMed Web of Science ®Google Scholar
• HermanSKrönkeGSchettGMolecular mechanisms of inflammatory bone damage; emerging targets for therapyTrends Mol Med200814624525318468489
   PubMed Web of Science ®Google Scholar
• BalAUniuEBaharGAydogEEksiogluEYorganciogluRComparison of IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitisClin Rheumatol200726221121516583185
   PubMed Web of Science ®Google Scholar
• ParkMCLeeSWChoiSTParkYBLeeSKSerum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitisScand J Rheumatol200736210110617476615
   PubMed Web of Science ®Google Scholar
• VisvanathanSWagnerCMariniJCInflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximabAnn Rheum Dis200867451151717644552
   PubMed Web of Science ®Google Scholar
• VisvanathanSvan der HeijdeDDeodharAEffects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitisAnn Rheum Dis200968217518218495735
   PubMed Web of Science ®Google Scholar
• SchellerJOhnesorgeNRose-JohnSInterleukin-6 trans-signaling in chronic inflammation and cancerScand J Immunol200663532132916640655
   PubMed Web of Science ®Google Scholar
• AxmannRBöhmCKrönkeGZwerinaJSmolenJSchettGInhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivoArthritis Rheum20096092747275619714627
   PubMed Web of Science ®Google Scholar